Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | GALK1 | P51570 | 1/20 | 0.34 |
| ▸ | CCR6 | P51684 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5482412 | 1.00 | NPSR1 (0.37) | NPSR1GRM5CYP3A4CNR2MAPT | |
| SCHEMBL5479822 | 1.00 | NPSR1 (0.37) | NPSR1GRM5CYP3A4CNR2MAPT | |
| SCHEMBL853694 | 0.79 | CNR2 (0.39) | GRM5CYP3A4CNR2L3MBTL1POLB | |
| SCHEMBL5480357 | 0.77 | GRM5 (0.43) | GRM5CYP3A4CNR2MAPTALDH1A1 | |
| SCHEMBL5480057 | 0.77 | GRM5 (0.43) | GRM5CYP3A4CNR2MAPTALDH1A1 | |
| SCHEMBL5480064 | 0.77 | GRM5 (0.43) | GRM5CYP3A4CNR2MAPTALDH1A1 | |
| SCHEMBL18143858 | 0.74 | NPSR1 (0.42) | NPSR1CNR2MAPTALDH1A1CA12 | |
| SCHEMBL12789001 | 0.71 | TPMT (0.42) | NPSR1CNR2MAPTALDH1A1CA12 | |
| SCHEMBL5483424 | 0.70 | TPMT (0.38) | NPSR1GRM5CYP3A4ALDH1A1L3MBTL1 | |
| SCHEMBL5480482 | 0.70 | FFAR1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202213-B2 | Combination therapy using a dual PPAR-α/PPAR-γ activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2007-04-10 | — | — | US | disclosed |
| US-20030199451-A1 | Combination therapy using a dual PPAR-a/PPAR-y activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders | HIGH POINT PHARMACEUTICALS, LLC | 2003-10-23 | — | — | US | disclosed |
| US-6569901-B2 | (E)-(S)-2-Ethoxy-3-(4-(5-phenyl-pent-2-en-4-ynyloxy)-phenyl)-propionic acid, ethyl ester for example; treating conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR); diabetes, obesity | NOVO NORDISK A/S (DK) | 2003-05-27 | — | — | US | disclosed |
| EP-1254102-A1 | ALKYNYLSUBSTITUTED PROPIONIC ACID DERIVATIVES AND THEIR USE AGAINST DIABETES AND OBESITY | Novo Nordisk A/S (DK) | 2002-11-06 | — | — | EP | disclosed |
| US-20010041709-A1 | New compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2001-11-15 | — | — | US | disclosed |
| WO-2001055086-A1 | ALKYNYLSUBSTITUTED PROPIONIC ACID DERIVATIVES AND THEIR USE AGAINST DIABETES AND OBESITY | NOVO NORDISK A/S (DK) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041709-A1 | New compounds, their preparation and use | PPARG, PPARD, PPARA | NPSR1 445/4885GRM5 615/4885CYP3A4 592/4885 |
| US-20030199451-A1 | Combination therapy using a dual PPAR-a/PPAR-y activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders | GLP1R, PPARG, PPARA | NPSR1 891/4885GRM5 279/4885CYP3A4 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.